Monday, November 16, 2026

EE497 Healthcare and Economic Impact of Friedreich's Ataxia in Italy: A Stratified Analysis Based On Patients’ Ambulatory Status

Ippazio Cosimo Antonazzo, Paolo Angelo Cortesi, Lorenzo G. Mantovani, Richard Lawson, Leila Khader, Claudia Oliviero, Laura Santoni, Antonio Cittadini, Gabriella Paparella, Francesco Saccà, EE497 Healthcare and Economic Impact of Friedreich's Ataxia in Italy: A Stratified Analysis Based On Patients’ Ambulatory Status, Value in Health, Volume 28, Issue 12, Supplement 1, 2025, Pages S203-S204, ISSN 1098-3015, doi:10.1016/j.jval.2025.09.879. 

 Loss of ambulation increases FA patient management costs from both NHS and societal perspectives.

Omaveloxolone functions as a molecular crowbar-like degrader of STING to alleviate aging-related inflammation

Zhou, J., Ma, X., Jiang, B. et al. Omaveloxolone functions as a molecular crowbar-like degrader of STING to alleviate aging-related inflammation. Nat Commun 17, 11202 (2026). doi:10.1038/s41467-026-77760-1 

Aberrant activation of the STING signaling pathway is involved with aging-related inflammation, yet no STING-targeting therapeutics are clinically approved. Here, we identify Omaveloxolone, an FDA-approved drug for Friedreich’s ataxia, as a potent STING degrader (DC50 = 118 nM, Dmax = 98.6%) via high-throughput screening. 

This study implicates Omaveloxolone as a molecular crowbar-like STING degrader and provides a mechanistic framework for targeting STING via conformational perturbation.

Larimar Narrows Q3 Loss; Completes BLA Submission For Nomlabofusp In Friedreich's Ataxia

Published: 11/16/2026. Larimar completed its rolling BLA submission to the U.S. Food and Drug Administration (FDA), seeking accelerated approval of nomlabofusp for adults and pediatric patients with Friedreich's ataxia. The application uses frataxin (FXN) as a potential novel surrogate endpoint.

BLA submission acceptance is expected in early 2027. An open-label study safety update is anticipated in the first quarter of 2027, followed by a potential U.S. approval in mid-2027, subject to FDA review. 

 If approved, Larimar is targeting a U.S. commercial launch in the third quarter of 2027. The company also expects to obtain and monetize a Rare Pediatric Disease Priority Review Voucher in mid-2027, if nomlabofusp receives approval.

Sunday, November 15, 2026

FXN protomutations are the source of pathogenic expanded GAA alleles in Friedreich ataxia and explain its unequal population distribution

Devore MC, Lam C, Xiao E, Devore J, McCain KRC, Wiley G, Park CC, Lynch DR, Bidichandani SI. FXN protomutations are the source of pathogenic expanded GAA alleles in Friedreich ataxia and explain its unequal population distribution. Hum Mol Genet. 2026 Jun 9;35(11):ddag046. doi: 10.1093/hmg/ddag046. PMID: 42262226; PMCID: PMC13248553. 

 These data indicate that FXN protomutations serve as a reservoir for the generation of premutation and E alleles, and for millennia have sustained the geographically-defined population distribution of FRDA.

Integration of Evolutionary Analysis With RFdiffusion for De Novo Design of Aggregation-Resistant Frataxin

Kırboğa KK, Küçüksille EU. Integration of Evolutionary Analysis With RFdiffusion for De Novo Design of Aggregation-Resistant Frataxin. Proteins. 2026 Jun;94(6):1225-1244. doi: 10.1002/prot.70114. Epub 2026 Jan 21. PMID: 41563298. 

 This work establishes a generalizable framework for therapeutic protein engineering where backbone redesign enables conformational ensemble modulation beyond the limitations of sequence optimization alone.

Nerve ultrasound as a biomarker in Friedreich’s ataxia

Giuseppe Di Pietro, Ettore Cioffi, Pietro Falco, Caterina Leone, Giulia Di Stefano, Eleonora Galosi, Gianfranco De Stefano, Valentina Martinez, Stefano Perotti, Carlo Casali, Andrea Truini,, PO 286 Nerve ultrasound as a biomarker in Friedreich’s ataxia, Clinical Neurophysiology, Volume 185, 2026, 2111295, ISSN 1388-2457, doi:10.1016/j.clinph.2025.2111295. 

 All patients exhibited severe sensory axonal neuropathy. HRUS showed significant CSA enlargement in the median and ulnar nerves at the axilla and upper arm. The number of affected nerve sites correlated directly with disability scores (SARA, FARS, mFARS, ADL 0-36, INCAT) and inversely with IADL.

Sex-based differences in the NRF2 oxidative stress response: Implications for precision therapeutics

Giusy Russomanno, Karolina Kwiatkowska, Ian M. Copple, Sex-based differences in the NRF2 oxidative stress response: Implications for precision therapeutics, Redox Biology, Volume 92, 2026, 104128, ISSN 2213-2317, doi:10.1016/j.redox.2026.104128. 

 Hormonal status, age, and tissue-specific receptor distribution further modulate these effects, suggesting that therapeutic responses to NRF2 activators are inherently sex-dependent. Pharmacokinetic and pharmacodynamic differences, including CYP3A-mediated metabolism and body composition, may additionally influence systemic exposure and safety profiles. Despite clinical use of NRF2 activators such as dimethyl fumarate and omaveloxolone, sex-stratified data on efficacy, dosing, and safety are scarce. This knowledge gap underscores the need for systematic evaluation of sex, hormonal milieu, and age in pharmacokinetic, pharmacodynamic, and clinical studies to ensure treatments are safe, effective, and equitable. Integrating these variables into research and clinical practice will optimise therapeutic benefits and minimise adverse events by accounting for patient-specific biology.



Nonclinical efficacy and safety evaluation of SGT-212, a novel investigational AAV FXN gene therapy for the treatment of Friedreich’s ataxia

Nonclinical efficacy and safety evaluation of SGT-212, a novel investigational AAV FXN gene therapy for the treatment of Friedreich’s ataxia, Brandon YH Chan, Jun Lee, Jamie Marshall, Matthew Harmelink, Gourav Roy Choudhury, Heather Born, Juliette Hordeaux, James M Wilson, Jessie Hanrahan, Gabriel Brooks, Nicolas Christoforou. Solid Biosciences, Charlestown, USA; University of Pennsylvania, Philadelphia, USA. doi:10.1016/j.nmd.2026.106596 

 These positive nonclinical data supported initiation of the Phase 1b FALCON trial (NCT07180355), an actively enrolling first-in-human study of SGT-212.

Genetic prevalence of repeat expansion and other rare neurological disorders in the Quebec population

De Mori A, Labrecque M, Triassi V, Audet S, Pelletier J, Lai A, La Piana R, Duquette A, Bhérer C and Tetreault M (2026) Genetic prevalence of repeat expansion and other rare neurological disorders in the Quebec population. Front. Genet. 17:1964104. doi: 10.3389/fgene.2026.1964104 

Among the diseases expected to be enriched in the CaG cohort given their established association with the French-Canadian founder effect, FXN and DMPK variants were identified at elevated frequencies, as anticipated. The high CF of FXN variants is consistent with the autosomal recessive nature of FRDA, in which carriers are unaffected and therefore not excluded during recruitment of CaG participants. The recent approval of omaveloxolone as a therapy for FRDA further increases the clinical value of identifying expansion carriers early in the Quebec population


Scatter plot comparing the prevalence per one hundred thousand people of seven diseases (SCA27B, ALS/FTD, DM1, SCA2, FRDA, SBMA Male, SBMA Female) across three data sources: CaG (blue squares), Global (orange squares), and Quebec (green squares). DM1 in Quebec shows the highest prevalence at one hundred fifty-seven point nine eight, while SBMA Female in CaG is lowest at zero point zero two. Prevalence varies notably by disease and data source.

Cells heal themselves: gene-edited hematopoietic stem cells restore frataxin deficiency in multiple organs

Lucy R. Osborne. Cells heal themselves: gene-edited hematopoietic stem cells restore frataxin deficiency in multiple organs. J Clin Invest. 2026;136(20):e211630. doi:10.1172/JCI211630. 

 There is undoubtedly a lot of work to be done optimizing the editing efficiency of the repeat expansion, cell engraftment, and the timing of delivery, but the results reported by Sivakumar et al. are very encouraging and demonstrate that even with relatively limited editing and chimerism, there were concrete improvements in neurological, pancreatic, and cardiac function in the humanized mouse model of FRDA.